Literature DB >> 22593614

Enhanced anti-serpin antibody activity inhibits autoimmune inflammation in type 1 diabetes.

Jan Czyzyk1, Octavian Henegariu, Paula Preston-Hurlburt, Raman Baldzizhar, Christine Fedorchuk, Enric Esplugues, Kim Bottomly, Frans K Gorus, Kevan Herold, Richard A Flavell.   

Abstract

Intracellular (clade B) OVA-serpin protease inhibitors play an important role in tissue homeostasis by protecting cells from death in response to hypo-osmotic stress, heat shock, and other stimuli. It is not known whether these serpins influence immunological tolerance and the risk for autoimmune diseases. We found that a fraction of young autoimmune diabetes-prone NOD mice had elevated levels of autoantibodies against a member of clade B family known as serpinB13. High levels of anti-serpinB13 Abs were accompanied by low levels of anti-insulin autoantibodies, reduced numbers of islet-associated T cells, and delayed onset of diabetes. Exposure to anti-serpinB13 mAb alone also decreased islet inflammation, and coadministration of this reagent and a suboptimal dose of anti-CD3 mAb accelerated recovery from diabetes. In a fashion similar to that discovered in the NOD model, a deficiency in humoral activity against serpinB13 was associated with early onset of human type 1 diabetes. These findings suggest that, in addition to limiting exposure to proteases within the cell, clade B serpins help to maintain homeostasis by inducing protective humoral immunity.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22593614      PMCID: PMC3370061          DOI: 10.4049/jimmunol.1200467

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  42 in total

1.  Critical role of cathepsin-inhibitors for autoantigen processing and autoimmunity.

Authors:  Naozumi Ishimaru; Rieko Arakaki; Nobuhiko Katunuma; Yoshio Hayashi
Journal:  Adv Enzyme Regul       Date:  2004

2.  Anti-GAD monoclonal antibody delays the onset of diabetes mellitus in NOD mice.

Authors:  V Menard; H Jacobs; H S Jun; J W Yoon; S W Kim
Journal:  Pharm Res       Date:  1999-07       Impact factor: 4.200

3.  Cathepsin L is essential for onset of autoimmune diabetes in NOD mice.

Authors:  René Maehr; Justine D Mintern; Ann E Herman; Ana-Maria Lennon-Duménil; Diane Mathis; Christophe Benoist; Hidde L Ploegh
Journal:  J Clin Invest       Date:  2005-09-22       Impact factor: 14.808

4.  Heterophile antibodies segregate in families and are associated with protection from type 1 diabetes.

Authors:  J X She; T M Ellis; S B Wilson; C H Wasserfall; M Marron; S Reimsneider; S C Kent; D A Hafler; D S Neuberg; A Muir; J L Strominger; M A Atkinson
Journal:  Proc Natl Acad Sci U S A       Date:  1999-07-06       Impact factor: 11.205

Review 5.  The NOD mouse: a model of immune dysregulation.

Authors:  Mark S Anderson; Jeffrey A Bluestone
Journal:  Annu Rev Immunol       Date:  2005       Impact factor: 28.527

6.  The ovalbumin family of serpin proteins.

Authors:  E Remold-O'Donnell
Journal:  FEBS Lett       Date:  1993-01-04       Impact factor: 4.124

7.  Prime role for an insulin epitope in the development of type 1 diabetes in NOD mice.

Authors:  Maki Nakayama; Norio Abiru; Hiroaki Moriyama; Naru Babaya; Edwin Liu; Dongmei Miao; Liping Yu; Dale R Wegmann; John C Hutton; John F Elliott; George S Eisenbarth
Journal:  Nature       Date:  2005-05-12       Impact factor: 49.962

8.  Insulin needs after CD3-antibody therapy in new-onset type 1 diabetes.

Authors:  Bart Keymeulen; Evy Vandemeulebroucke; Anette G Ziegler; Chantal Mathieu; Leonard Kaufman; Geoff Hale; Frans Gorus; Michel Goldman; Markus Walter; Sophie Candon; Liliane Schandene; Laurent Crenier; Christophe De Block; Jean-Marie Seigneurin; Pieter De Pauw; Denis Pierard; Ilse Weets; Peppy Rebello; Pru Bird; Eleanor Berrie; Mark Frewin; Herman Waldmann; Jean-François Bach; Daniel Pipeleers; Lucienne Chatenoud
Journal:  N Engl J Med       Date:  2005-06-23       Impact factor: 91.245

9.  Effects of autoimmunity and immune therapy on beta-cell turnover in type 1 diabetes.

Authors:  Nicole A Sherry; Jake A Kushner; Mariela Glandt; Tadahiro Kitamura; Anne-Marie B Brillantes; Kevan C Herold
Journal:  Diabetes       Date:  2006-12       Impact factor: 9.461

10.  Following a diabetogenic T cell from genesis through pathogenesis.

Authors:  J D Katz; B Wang; K Haskins; C Benoist; D Mathis
Journal:  Cell       Date:  1993-09-24       Impact factor: 41.582

View more
  6 in total

1.  Cellular proliferation in mouse and human pancreatic islets is regulated by serpin B13 inhibition and downstream targeting of E-cadherin by cathepsin L.

Authors:  Chi-Wen Lo; Yury Kryvalap; Tzong-Jen Sheu; Ching-Ho Chang; Jan Czyzyk
Journal:  Diabetologia       Date:  2019-03-01       Impact factor: 10.122

Review 2.  Serpins, immunity and autoimmunity: old molecules, new functions.

Authors:  Mariele Gatto; Luca Iaccarino; Anna Ghirardello; Nicola Bassi; Patrizia Pontisso; Leonardo Punzi; Yehuda Shoenfeld; Andrea Doria
Journal:  Clin Rev Allergy Immunol       Date:  2013-10       Impact factor: 8.667

3.  Antibody Response to Serpin B13 Induces Adaptive Changes in Mouse Pancreatic Islets and Slows Down the Decline in the Residual Beta Cell Function in Children with Recent Onset of Type 1 Diabetes Mellitus.

Authors:  Yury Kryvalap; Chi-Wen Lo; Ekaterina Manuylova; Raman Baldzizhar; Nicholas Jospe; Jan Czyzyk
Journal:  J Biol Chem       Date:  2015-11-17       Impact factor: 5.157

Review 4.  Islet inflammation: a unifying target for diabetes treatment?

Authors:  Yumi Imai; Anca D Dobrian; Margaret A Morris; Jerry L Nadler
Journal:  Trends Endocrinol Metab       Date:  2013-02-26       Impact factor: 12.015

5.  Anti-serpin antibody-mediated regulation of proteases in autoimmune diabetes.

Authors:  Raman Baldzizhar; Christine Fedorchuk; Mithilesh Jha; Chozhavendan Rathinam; Octavian Henegariu; Jan Czyzyk
Journal:  J Biol Chem       Date:  2012-11-29       Impact factor: 5.157

Review 6.  The Role of Proteases and Serpin Protease Inhibitors in β-Cell Biology and Diabetes.

Authors:  Yury Kryvalap; Jan Czyzyk
Journal:  Biomolecules       Date:  2022-01-02
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.